Welcome to LookChem.com Sign In|Join Free
  • or

503612-47-3

Post Buying Request

503612-47-3 Suppliers

Recommended suppliersmore

Product FOB Price Min.Order Supply Ability Supplier
1-(4-methoxy-phenyl)-7-oxo-6-[4-(2-oxo-piperidin-1-yl)-phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid amide 503612-47-3
Cas No: 503612-47-3
No Data No Data Metric Ton/Day Jiangsu Allyrise Pharmaceutical Co., Ltd. Contact Supplier
Apixaban
Cas No: 503612-47-3
No Data 20 Gram 2 Metric Ton/Year Jinan Jianfeng Chemical Co., Ltd Contact Supplier
Apixaban
Cas No: 503612-47-3
No Data 1 Gram 500 Kilogram/Month Huarong Industrial Group Ltd. Contact Supplier
Apixaban
Cas No: 503612-47-3
No Data No Data No Data Koning Pharmchem Co., Ltd. Contact Supplier
Apixaban manufacturer|High quality|Best price|In stock CAS.503612-47-3
Cas No: 503612-47-3
USD $ 1.0-3.0 / Kilogram 1 Kilogram 10 Kilogram/Day Hebei yanxi chemical co.,LTD. Contact Supplier
CAS:503612-47-3 Apixaban low price
Cas No: 503612-47-3
No Data 1 Kilogram 100 Kilogram/Week Kono Chem Co.,Ltd Contact Supplier
High quality Apixaban supplier in China
Cas No: 503612-47-3
No Data No Data No Data Simagchem Corporation Contact Supplier
Apixaban manufacturer
Cas No: 503612-47-3
No Data 1 Gram 500 Metric Ton/Month Anhui Dexinjia Biopharm Co., Ltd Contact Supplier
Apixaban
Cas No: 503612-47-3
No Data 1 Gram Metric Ton/Day Shenzhen READLINE Technology Co., Ltd. Contact Supplier
Apixaban Manufacturer/High quality/Best price/In stock
Cas No: 503612-47-3
USD $ 3.0-3.0 / Kilogram 1 Kilogram 1-100 Metric Ton/Month Hangzhou Dayangchem Co., Ltd. Contact Supplier

503612-47-3 Usage

Warnings and Precautions

  • Breastfeeding mothers should stop usage or stop breastfeeding.
  • Use during pregnancy is not advised.
  • Use while experiencing severe liver damage is not advised.

Definition

ChEBI: A pyrazolopyridine that is 7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide substituted at position 1 by a 4-methoxyphenyl group and at position 6 by a 4-(2-oxopiperidin-1-yl)phenyl group. It is used for the prevention and treatment of thromboembolic diseases.

Clinical Research

Apixaban is the third new oral anticoagulant to go on sale, following dabigatran and rivaroxaban, and it has already been approved in Europe for preventing venous thromboembolism in patients undergoing elective hip or knee replacement surgery. Out of these three oral anticoagulants approved in Europe, compared to the current standard preventative treatment against venous thromboembolism, enoxaparin, rivaroxaban excelled in the record experiment, and apixaban excelled in the advance experiment. Rivaroxaban’s curative effects were slightly superior, but it caused more severe bleeding than apixaban. Researchers attributed these differences to medication time, as rivaroxaban was taken 6-8 hours after surgery in the record experiment, while apixaban was used 18 hours after surgery in the advance experiment. These drugs have better curative effect when used closer to time of surgery, but also have an increased bleeding risk. Clinical research showed that compared to a daily subdermal injection of 40mg enoxaparin, 2 oral 2.5mg dosages of apixaban had better preventative effects against venous thromboembolism following hip or knee replacement surgery and did not increase bleeding risk.

Indications and Usage

Apixaban is a new form of oral anticoagulant drug developed by Bristol Myers Squibb and Pfizer. It is a new form of oral Xa factor inhibitor, and its commercial name is Eliquis. Apixaban is used to treat adult patients undergoing elective hip or knee replacement surgery to prevent venous thromboembolism (VTE)

Mechanisms of Action

Apixaban is an oral selective activated Xa factor inhibitor and can prevent thrombin generation and thrombosis.

References

https://en.wikipedia.org/wiki/Apixaban
https://www.drugbank.ca/drugs/DB06605

Uses

Apixaban is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively.

Drug Interactions

1.A double inhibitor of strong CYP3A4 and P-gp increases apixaban’s blood levels: decrease Eliquis dosage to 2.5mg or avoid simultaneous usage.
2.A inductor of strong CYP3A4 and P-gp can decrease apixaban’s blood levels: avoid simultaneous usage.
InChI:InChI=1/C25H25N5O4/c1-34-19-11-9-18(10-12-19)30-23-20(22(27-30)24(26)32)13-15-29(25(23)33)17-7-5-16(6-8-17)28-14-3-2-4-21(28)31/h5-12H,2-4,13-15H2,1H3,(H2,26,32)

503612-47-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 20, 2017

Revision Date: Aug 20, 2017

1.Identification

1.1 GHS Product identifier

Product name apixaban

1.2 Other means of identification

Product number -
Other names 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5-dihydropyrazolo[3,4-c]pyridine-3-carboxamide

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:503612-47-3 SDS

Please post your buying leads,so that our qualified suppliers will soon contact you!

*Required Fields